Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 14 04:00PM ET
13.91
Dollar change
0.00
Percentage change
0.00
%
IndexRUT P/E- EPS (ttm)- Insider Own17.74% Shs Outstand26.88M Perf Week26.00%
Market Cap375.01M Forward P/E- EPS next Y-2.72 Insider Trans0.31% Shs Float22.18M Perf Month2.13%
Income- PEG- EPS next Q-0.64 Inst Own68.19% Short Float18.56% Perf Quarter-10.26%
Sales- P/S- EPS this Y73.16% Inst Trans27.06% Short Ratio12.82 Perf Half Y-1.70%
Book/sh6.67 P/B2.09 EPS next Y-4.26% ROA- Short Interest4.12M Perf Year-
Cash/sh7.16 P/C1.94 EPS next 5Y- ROE- 52W Range7.91 - 24.00 Perf YTD-32.80%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-42.04% Beta-
Dividend TTM- Quick Ratio19.85 Sales past 5Y-50.00% Gross Margin- 52W Low75.85% ATR (14)0.85
Dividend Ex-Date- Current Ratio19.85 EPS Y/Y TTM- Oper. Margin- RSI (14)64.23 Volatility7.15% 7.07%
Employees63 Debt/Eq0.06 Sales Y/Y TTM- Profit Margin- Recom1.14 Target Price33.16
Option/ShortYes / Yes LT Debt/Eq0.04 EPS Q/Q-198166.67% Payout- Rel Volume0.00 Prev Close13.91
Sales Surprise- EPS Surprise8.63% Sales Q/Q- EarningsAug 13 AMC Avg Volume320.97K Price13.91
SMA2015.34% SMA5019.96% SMA2005.15% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Sep-03-24Initiated Wedbush Outperform $29
Feb-27-24Initiated William Blair Outperform
Feb-27-24Initiated TD Cowen Outperform
Feb-27-24Initiated Stifel Buy $32
Feb-27-24Initiated Robert W. Baird Outperform $32
Feb-27-24Initiated Jefferies Buy $33
Sep-05-24 09:27AM
Sep-04-24 08:05AM
Sep-03-24 08:05AM
Aug-13-24 04:05PM
Jul-25-24 08:30AM
07:30AM Loading…
Jul-16-24 07:30AM
Jul-12-24 01:58PM
Jun-20-24 08:05AM
Jun-18-24 08:05AM
Jun-10-24 09:00AM
May-29-24 08:05AM
May-21-24 08:05AM
May-14-24 10:54PM
04:03PM
May-09-24 08:05AM
08:05AM Loading…
Apr-23-24 08:05AM
Apr-10-24 03:30PM
Apr-09-24 09:37AM
Apr-03-24 08:05AM
Mar-21-24 04:05PM
Mar-11-24 08:05AM
Mar-07-24 08:00AM
Feb-27-24 08:00AM
Feb-06-24 04:05PM
Feb-01-24 08:57PM
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Savitz AdamCHIEF MEDICAL OFFICERJul 09 '24Buy12.6012,069152,08536,920Jul 11 04:15 PM
Savitz AdamCHIEF MEDICAL OFFICERJul 10 '24Buy13.222,93138,74839,851Jul 11 04:15 PM
Smith Nicholas ConradCHIEF FINANCIAL OFFICERMar 28 '24Buy16.366,150100,62826,866Apr 01 04:15 PM
Alpha Wave Global, LP10% OwnerFeb 06 '24Buy16.00600,0009,600,0003,707,757Feb 08 04:32 PM
Smith Nicholas ConradCHIEF FINANCIAL OFFICERFeb 06 '24Buy16.001,56325,0081,563Feb 07 04:40 PM
Savitz AdamCHIEF MEDICAL OFFICERFeb 06 '24Buy16.0017,000272,00024,851Feb 07 04:38 PM
Etkin AmitPRESIDENT AND CEOFeb 06 '24Buy16.003,12550,0001,205,465Feb 07 04:36 PM